R espiratory syncytial virus (RSV)
3 is the leading cause of lower respiratory tract infection and hospitalization in young children under 5 years of age (1) . Despite the clear need, a safe and effective RSV vaccine has yet to be developed. A series of RSV vaccine trials were conducted in the 1960s using a formalin-inactivated (FI)-RSV preparation. In these trials, ϳ80% of FI-RSV vaccinees were hospitalized and tragically two children died following a subsequent RSV exposure (2) (3) (4) . Histological analyses of the deceased vaccinees revealed pulmonary eosinophilia (2, 4, 5) . Additionally, increased levels of circulating eosinophils were detected in the peripheral blood of numerous vaccinees (5) . Work performed using mouse models of RSV vaccine-enhanced disease indicate that CD4 T cells and Th2 cells are required for the development of pulmonary eosinophilia (6 -8) . These data suggest that the FI-RSV vaccine primed the children for a Th2 response.
A great deal of our current understanding of the underlying mechanisms that mediate the induction of RSV vaccine-enhanced pulmonary eosinophilia comes from the BALB/c mouse model. BALB/c mice immunized with either FI-RSV or a recombinant vaccinia virus (vacv) that expresses the RSV attachment (G) glycoprotein (vacvG) mount an RSV-specific CD4 T cell response and do not generate a detectable RSV-specific CD8 T cell response (9) . RSV challenge of either FI-RSV-or vacvG-immunized mice results in a robust memory CD4 T cell response, the development of pulmonary eosinophilia, and systemic disease (i.e., weight loss), thus mimicking the enhanced disease that was observed in the FI-RSV-vaccinated children (9 -12) . Interestingly, the secondary G-specific CD4 T cell response that occurs after RSV challenge of vacvG-immunized mice is largely oligoclonal for the V␤14 chain of the TCR (8) . Furthermore, depletion of V␤14 ϩ CD4 T cells in vacvG-immunized mice prevents the development of pulmonary eosinophilia after RSV challenge (8) . These data indicate that V␤14 ϩ CD4 T cells are required for the development of RSV vaccine-enhanced disease.
Fas ligand (FasL; CD178) is a type II TNFR family member that plays a critical role in the control of the immune system by binding to its receptor Fas (CD95). FasL is constitutively expressed in immune-privileged tissues (e.g., eye, uterus, and testis) where it is thought to induce the death of tissue-infiltrating immune cells that express Fas (13) . Intriguing recent work has demonstrated that Fas-FasL interactions may induce bidirectional signaling, sending a death signal through Fas, as well as a signal through FasL (14) . Signaling through FasL has been shown to be required for the full expansion of allogeneic CD8 T cells, suggesting that FasL signals may promote T cell proliferation and survival (15, 16) .
FasL also plays a critical role in T cell-mediated clearance of respiratory pathogens and has also been previously shown to be required for the full expansion and effector function of T cells after antigenic stimulation (15) (16) (17) . Interestingly, gld mice that are deficient in functional FasL exhibit delayed viral clearance and reduced morbidity after influenza virus infection as compared with wild-type (WT) mice (18) . Similar to influenza virus-infected mice, RSV-infected gld mice also exhibit decreased weight loss and delayed viral clearance after primary infection as compared with WT mice (19) . Taken together, these data suggest that FasL is involved in viral clearance as well as the development of immunopathology after respiratory virus infection. However, the role of FasL in the development of RSV vaccine-enhanced disease has not been examined.
In these studies we used gld mice to question the role of FasL in the development of RSV vaccine-enhanced disease. The gld mice used suffer from lymphadenopathy and systemic autoimmunity that increase in severity with the age of the mouse (20) . We specifically chose to use gld mice over lpr mice, which lack Fas, for these studies because we were interested in also assessing the potential role of FasL expressed by CD8 T cells in mediating the inhibition of RSV vaccine-enhanced pulmonary eosinophilia (see Ref. 9) . We demonstrate that functional FasL is required for the development of RSV vaccine-enhanced disease. FasL-defective gld mice immunized with vacvG exhibit reduced weight loss and clinical illness after RSV challenge as compared with their WT counterparts. Furthermore, vacvG-immunized gld mice also exhibit reduced levels of pulmonary eosinophilia and a diminished secondary RSV G-specific CD4 T cell response after RSV challenge. In agreement with this observation, FI-RSV-immunized mice also demonstrate reduced pulmonary eosinophilia and CD4 T cell responses in the lung. Both WT and gld mice exhibit a similar number of primary RSV G-specific CD4 T cells after vacvG immunization; however, secondary memory G-specific CD4 T cells in gld mice fail to fully expand after RSV challenge. These data suggest that CD4 T cells undergoing a secondary response to Ag require functional FasL for their full expansion. Interestingly, both primary and secondary RSV-specific CD8 T cell responses in gld mice are similar to WT controls, suggesting that the expansion of memory CD4 and CD8 T cells have different requirements for FasL.
Materials and Methods

Viruses and infection of mice
The A2 strain of RSV was a gift from B. S. Graham (National Institutes of Health, Bethesda, MD) and was propagated in HEp-2 cells (American Type Culture Collections (ATCC)). Recombinant vacv were a gift from T. J. Braciale (University of Virginia, Charlottesville, VA) and J.L. Beeler (U.S. Food and Drug Administration, Bethesda, MD) and were propagated in BSC-40 cells (ATCC). BALB/cAnNCr mice between 6 and 10 wk of age were purchased from the National Cancer Institute (Bethesda, MD). CPt.C3-Fasl gld /J mice (referred to in this study as gld mice) were a gift from K. L. Legge (University of Iowa, Iowa City, IA). Mice were scarified with 3 ϫ 10 6 PFU of recombinant vacv or a mixture of two different recombinant vacv and challenged with RSV 3 wk later as previously described (9) . Alternatively, either WT or gld mice were immunized i.m. with a 1/200 dilution of either FI-RSV or a formalin-inactivated mock preparation of HEp-2 cell supernatants as previously described (21) . Four weeks after either mock or FI-RSV immunization, mice were challenged intranasally with 3 ϫ 10 6 PFU of RSV. In some instances, mice were weighed and assigned a clinical illness score on a daily basis after RSV challenge as previously described (22) . All mouse experiments have been evaluated and approved by the University of Iowa Animal Care and Use Committee.
Mononuclear cell isolation and intracellular cytokine staining
Lung mononuclear cells and bronchial alveolar lavage (BAL) cells were harvested and prepared as previously described (9) . Cytospin (Cytospin 2; Shandon) preparations of BAL cells were stained with Diff-Quik (Baxter Healthcare) before analysis. Differential cell counts were performed on at least 200 cells based on standard morphology and staining characteristics. In some cases, eosinophils were identified by FACS using the markers CD45 (eBioscience), CD11c (eBioscience), and Siglec F (BD Pharmingen) as previously described (23) . Cells from the spleen and mediastinal lymph nodes (MedLN) were isolated by pressing these tissues between the ends of frosted glass slides (Surgipath). Peptides corresponding to the RSV-derived CD4 T cell epitope G [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] and the CD8 T cell epitope M2 82-90 were purchased from Bio-Synthesis. To enumerate the number of RSV-specific CD4 and CD8 T cells, 1-2 ϫ 10 6 lung mononuclear cells were stimulated in vitro in the presence of 1 M peptide and 10 g/ml brefeldin A (SigmaAldrich) for 5 h at 37°C. After stimulation, cells were subsequently stained for cell surface CD4, CD8, and Thy1.2 (all mAbs from eBioscience). Cells were subsequently washed twice with cold staining buffer and then fixed for 15 min with FACS lysing solution (BD Biosciences). After fixation, cells were incubated at 4°C for 10 min in the presence of staining buffer containing 0.5% saponin to permeabilize the cells. Cells were subsequently stained for intracellular IFN-␥ or IL-13 (all mAbs from eBioscience) in the presence of permeabilization buffer. Cells were then washed an additional two times with permeabilization buffer and once more with staining buffer before final resuspension in staining buffer. All samples were analyzed on a BD FACSCanto flow cytometer. Staining for TCR V␤ chain usage was done using a panel of V␤ Abs (BD Pharmingen). Data were analyzed using FlowJo software (Tree Star). Peripheral blood was collected from isoflourane-anesthetized mice by eye bleed into 4% (w/v) sodium citrate. RBC in the peripheral blood were lysed with 0.84% NH 4 Cl and washed with RPMI 1640.
Plaque assays
Lungs were harvested from either WT or gld vacv-immunized mice on day 4 or 7 after RSV challenge in 1 ml of serum-free RPMI 1640. Lung tissue was disrupted using a tissue homogenizer (Ultra-Turrax T25; IKA) and lung homogenates were then centrifuged at 2000 rpm for 10 min. Cell-free supernatants from these samples were flash frozen in liquid nitrogen and stored at Ϫ80°C. Dilutions of thawed lung homogenates were incubated on Vero cells (ATCC) in 6-well plates (BD Falcon) for 1.5 h at 37°C with gentle rocking. Cells were subsequently overlaid with 4 ml of 1% Seakem ME agarose (Cambrex) in Eagle's MEM (Cambrex) and allowed to incubate for 5 days at 37°C. After 5 days of incubation, cells were overlaid again with 2 ml of 1% agarose in Eagle's MEM containing a final concentration of 0.01% neutral red (Sigma-Aldrich) and allowed to incubate an additional 24 h. The number of plaques was counted with the aid of a light box.
Activated caspase 3/7 and Annexin V staining
Mononuclear (1 ϫ 10 6 ) cells from each tissue were stained with either Annexin V (BD Pharmigen) or for activated caspase 3/7 (Vybrant Fam; Molecular Probes) as per the manufacturer's instructions. Cells stained with Annexin V were stained with Abs specific to CD4 and V␤14 as described before staining with Annexin V. Cells stained for activated caspase 3/7 were stained after caspase staining with Abs specific for CD4 and V␤14 as described.
Data analysis and statistics
Statistical analyses were performed using Prism software (GraphPad). Data were analyzed using Student's t test or, where indicated, by ANOVA followed by a Tukey post-test. Differences were considered significant when p Ͻ 0.05.
Results
Systemic disease is reduced in vacvG-immunized gld mice after RSV challenge
BALB/c mice exhibit weight loss and clinical illness following an acute RSV infection (19) . Previous work has demonstrated that gld mice exhibit reduced weight loss and clinical illness following an acute RSV infection as compared with WT controls (19) . Compared to mice with an acute RSV infection, vacvG-immunized mice exhibit exacerbated weight loss and clinical illness (6, 22, 24) . To determine the role of FasL in the development of weight loss and clinical illness in G protein-primed mice, WT and gld mice were immunized with either vacv that expresses ␤-galactosidase (␤-gal) or vacvG followed 21 days later by RSV challenge. After RSV challenge, WT vacvGimmunized mice lost significantly more weight ( p Ͻ 0.05) as compared with vacv␤-gal-immunized controls peaking between days 4 and 5 after RSV challenge (Fig. 1A ). This peak in weight loss also correlates with the peak in clinical illness in WT vacvG-immunized mice (Fig. 1B) . In contrast, vacvG-immunized gld mice did not exhibit significantly enhanced weight loss or clinical illness ( p Ͼ 0.05) after RSV challenge as compared with vacv␤-gal-immunized gld controls ( Fig. 1 ). These data indicate that FasL is required for the development of systemic disease after RSV challenge of mice previously immunized with vacvG.
The gld mice exhibit reduced pulmonary eosinophilia and CD4 T cell responses
CD4 T cells play a prominent role in the development of RSV vaccine-enhanced disease by inducing systemic disease and pulmonary pathology (7, 8) . For instance, adoptive transfer of in vitro stimulated CD4 T cells from vacvG-immunized mice results in both weight loss and the development of pulmonary eosinophilia after RSV challenge (25) . Furthermore, depletion of V␤14 ϩ CD4
T cells from vacvG-immunized mice results in decreased pulmonary eosinophilia and systemic disease (8) . As noted, vacvG-immunized gld mice exhibited decreased systemic disease as compared with their WT counterparts. We therefore questioned whether or not vacvG-immunized gld mice would also exhibit decreased levels of pulmonary eosinophilia. Fig. 2 demonstrates that neither vacv␤-gal-immunized WT nor gld mice develop pulmonary eosinophilia after RSV challenge. WT mice immunized with vacvG develop extensive pulmonary eosinophilia after RSV challenge, but interestingly the frequency ( Fig. 2A ) and total number (Fig. 2B ) of eosinophils in the BAL is significantly reduced ( p Ͻ 0.05) in vacvG-immunized gld mice. However, there is a significant increase ( p Ͻ 0.05) in both the frequency ( Fig. 2A ) and total number (Fig. 2B ) of eosinophils in vacvG-immunized gld mice as compared with vacv␤-gal-immunized gld control mice. Because T cells are associated with both systemic disease and pulmonary pathology, we examined the T cell responses following RSV challenge of vacv-immunized WT and gld mice. Total mononuclear cell infiltration was similar in both vacv␤-gal and vacvGimmunized WT and gld mice at day 7 after RSV challenge (Fig.  3A) . The RSV attachment (G) protein contains a single CD4 T cell epitope that lies between aa 183-195 (26) . The RSV transcription anti-termination factor (M2) protein contains an immunodominant CD8 T cell epitope that lies between aa 82-90 (27) . The total number of CD8 T cells (Fig. 3B) and RSV M2 82 -specific CD8 T cells (Fig. 3C ) was similar in WT and gld mice. However, there was a significant reduction ( p Ͻ 0.05) in the total number of CD4 T cells (Fig. 3D ) and RSV G 183 -specific CD4 T cells (Fig. 3E ) in the lungs of vacvG-immunized gld mice as compared with WT controls. The total number of CD4 T cells in the lungs is decreased 2-to 3-fold in vacvG-immunized gld mice as compared with vacvG-immunized WT controls (Fig. 3D) . However, the total number of RSV G 183 -specific CD4 T cells in the lung is decreased ϳ10-fold in vacvG gld mice as compared with vacvG-immunized WT controls (Fig. 3E) . These data indicate that the decrease in CD4 T cells in vacvG-immunized gld mice is largely Ag-specific. To determine whether or not the decrease in the total number of RSV G 183 -specific CD4 T cells was observed only in the lung, we examined the total number of these cells in other tissues. There were also significantly ( p Ͻ 0.05) fewer G 183 -specific CD4 T cells in the spleen and BAL in vacvG-immunized gld mice as compared with vacvG-immunized WT controls (Fig. 3F ). These data suggest that the magnitude of the secondary RSV-specific CD4 T cell response is decreased in mice lacking functional FasL.
We have previously demonstrated that IL-13 is required for the development of pulmonary eosinophilia after RSV challenge of mice previously immunized with vacvG (22) . We therefore examined the total number of IL-13-producing RSV G 183 -specific CD4 T cells by intracellular cytokine staining after RSV challenge of either WT or gld mice that had been previously immunized with vacvG. The gld mice had a significantly reduced ( p Ͻ 0.05) total number of IL-13 ϩ G 183 -specific CD4 T cells in the lung and BAL at day 7 after RSV challenge (Fig. 3G) . The total number of IL-13-producing G 183 -specific CD4 T cells fell below the level of detection (less than 1 ϫ 10 4 cells) in the MedLN in gld mice as compared with WT controls (Fig. 3G ). We were unable to detect IL-13-producing RSV G 183 -specific CD4 T cells in the spleens of both vacvG-immunized WT and gld mice (Fig. 3G) . Interestingly, the decrease in the total number of IFN-␥-producing (Th1) and IL-13-producing (Th2) cells is similar (ϳ10-fold) in gld mice as compared with WT mice (Fig. 3, F and G) , suggesting that FasL plays a similar role in the expansion of these two different CD4 T cell subsets.
Previous work has demonstrated that RSV challenge of mice previously immunized with vacvG elicits a RSV G 183 -specific memory CD4 T cell response that is largely oligoclonal and expresses the V␤14 chain of the TCR (8) . Furthermore, these V␤14 ϩ CD4 T cells are required for the development of RSV vaccine-enhanced disease (8) . Figs. 1 and 2 demonstrated that vacvG-immunized gld mice exhibited diminished systemic disease as well as a decreased number of eosinophils in the lung airway as compared with WT controls. We therefore hypothesized that the V␤14 ϩ CD4 T cell response would also be diminished in these mice. Fig. 4 demonstrates that both naive WT and gld mice exhibit a similar distribution of V␤ usage among naive CD4 T cells in the spleen as there were not enough cells in the lung of naive mice to analyze (Fig. 4A) . However, after RSV challenge of vacvG-immunized mice, there was a significant decrease ( p Ͻ 0.05) in the frequency of TCR V␤14 ϩ CD4 T cells in the lung (Fig. 4B) . Notably, this decrease in V␤14 ϩ CD4 T cells was not compensated for by expression of alternative V␤ chains (Fig. 4B) . Taken together, these data strongly suggest a role for FasL in the expansion or survival of secondary memory CD4 T cells. These data also demonstrate that the lack of systemic disease and pulmonary pathology in gld mice correlates with a decreased number of diseasecausing V␤14 ϩ CD4 T cells (8). 
Only RSV-specific memory CD4 T cell responses are defective in gld mice
We have demonstrated that the secondary RSV G 183 -specific CD4 T cell response in the lung is dramatically decreased in vacvGimmunized gld mice as compared with WT mice (Fig. 3E) . To further elucidate the mechanism controlling the decreased total number of secondary RSV G 183 -specific CD4 T cells in vacvGimmunized gld mice after RSV challenge, we quantified the total number of G 183 -specific CD4 T cells early after vacvG immunization (day 8) and prior to RSV challenge (day 21 after vacvG immunization). There were a similar total number of RSV G 183 -specific CD4 T cells in the spleens of WT and gld vacvG-immunized mice at both 8 and 21 days after vacvG immunization (Fig.  5) . These data suggest that there is no defect in the ability to generate a primary RSV G 183 -specific CD4 T cell response in the absence of functional FasL. These data instead indicate that FasL is required for the generation of the RSV G 183 -specific secondary memory CD4 T cell response. Our earlier results also demonstrated that the generation of a primary RSV M2 82 -specific CD8 T cell response is unaltered in the lung after RSV challenge of either vac␤-gal or vacvG-immunized WT and gld mice (Fig. 3C) . Therefore, we next questioned whether or not the generation of a memory CD8 T cell response also requires FasL. In these experiments, mice were immunized with a recombinant vacv that expresses a chimeric G protein that contains the immunodominant M2 82-90 CD8 T cell epitope (vacvG/M2) (28) . Mice previously immunized with vacvG/M2 generate a robust M2 82 -specific CD8 T cell response after RSV challenge (9, 28) . In contrast to the RSV G 183 -specific CD4 T cell response, neither the primary (vacv␤-gal-immunized) nor the memory (vacvM2-immunized) M2 82 -specific CD8 T cell response was significantly altered ( p Ͼ 0.05) in gld mice as compared with WT mice (Fig. 6) . The RSV G 183 -specific CD4 T cell response was not significantly different in either WT or gld vacvG/M2-immunized mice (data not shown). This is likely due to the already decreased total number of RSV G 183 -specific CD4 T cells observed in vacvG/M2-immunized mice after RSV challenge (9) . These data suggest that CD4, but not CD8, T cells require functional FasL to fully expand or survive upon secondary exposure to Ag.
Viral titers in vacv-immunized WT and gld mice
As described, we observed a dramatic decrease in the total number of RSV G 183 -specific CD4 T cells in the lungs of gld vacvGimmunized mice as compared with their WT counterparts after RSV challenge. Because the clearance of RSV is delayed after acute infection of gld mice, we determined whether or not viral clearance was similar after RSV challenge of WT and gld mice that had been previously immunized with vacvG. As demonstrated previously (9), vacvG-immunized WT mice clear virus more efficiently than vacv␤-gal-immunized mice by day 4 after RSV challenge (Fig. 7) . Furthermore, RSV is completely cleared from the lungs of both WT vacvG-and vacv␤-gal-immunized mice by day 7 after RSV challenge (Fig. 7) . In contrast, vacvG-immunized gld mice exhibited significantly higher ( p Ͻ 0.05) virus titers than WT mice at day 4 postinfection. In contrast to WT mice, we were still able to detect virus in the lungs of vacvG-immunized gld mice at day 7 after RSV challenge. Likewise, vacv␤-gal-immunized gld mice failed to clear virus by day 7 postinfection (Fig. 7) . These data suggest that the diminished CD4 T cell response observed in vacvG-immunized gld mice correlates with delayed viral clearance.
Decreased eosinophilia and CD4 T cell responses in FI-RSV-immunized gld mice
Our results depicted in Fig. 4B demonstrate a reduced V␤14 ϩ CD4 T cell response in vacvG-immunized gld mice as compared with their WT counterparts. Previous work has shown that this V␤14 ϩ CD4 T cell response is required for the development of pulmonary eosinophilia after RSV challenge of vacvG-immunized mice, but not in mice previously immunized with FI-RSV (8, 29) . Therefore, we questioned whether or not gld mice immunized with FI-RSV would also develop reduced pulmonary eosinophilia and CD4 T cell responses after RSV challenge as compared with FI-RSVimmunized WT mice. As expected, WT FI-RSV-immunized mice develop extensive pulmonary eosinophilia after RSV challenge as compared with mock-immunized controls (Fig. 8A) . In contrast, gld mice previously immunized with either FI-RSV or a mock control exhibited a significant ( p Ͻ 0.05) reduction in the total number of eosinophils in the BAL after RSV challenge as compared with their WT counterparts (Fig. 8A) . The specificity of CD4 T cells in FI-RSV-immunized mice after RSV challenge is currently unknown (29) . Therefore we measured the total number of CD4 T cells in the lung at day 7 after RSV challenge of either FIGURE 6. Memory RSV M2 82 -specific CD8 T cell responses in WT and gld mice. WT or gld BALB/c mice were immunized with either 3 ϫ 10 6 PFU of vacv␤-gal or vacvG and 3 wk later challenged intranasally with 3 ϫ 10 6 PFU of RSV. Lung mononuclear cells were then stained with RSV M2 82 -specific tetramers and Abs to Thy1.2 and CD8 and the total number of M2 82 -specific CD8 T cells was determined by flow cytometry. Representative data from one of two individual experiments are shown with n ϭ 3-4 mice per group. Error bar represents the SEM; n.s., not significant. mock-or FI-RSV-immunized mice. Consistent with our observations in vacvG-immunized WT and gld mice (Fig. 3D) , there was a significant reduction ( p Ͻ 0.05) in the total number of CD4 T cells in the lungs after RSV challenge of both mock-and FI-RSVimmunized gld mice as compared with their WT counterparts (Fig.  8B) . Taken together, these data suggest that the decreased memory CD4 T cell response observed after RSV challenge of either vacvG-or FI-RSV-immunized gld mice is independent of the Ag specificity of the memory CD4 T cells.
Increased frequency of apoptotic CD4 T cells in secondary lymphoid tissues of gld mice
The gld mice exhibit a decreased total number of RSV G 183 -specific CD4 T cells after RSV challenge as compared with WT mice (Fig. 3E) . It is unclear whether this difference is due to the inability of FasL-deficient memory CD4 T cells to either fully expand or survive after RSV challenge. The V␤14 chain of the TCR is expressed on the majority of RSV G 183 -specific CD4 T cells and has been previously used as a surrogate to identify RSV G 183 -specific CD4 T cells after RSV challenge of vacvG-immunized mice (30). To determine whether or not V␤14 ϩ CD4 T cells fail to accumulate after RSV challenge due to enhanced apoptosis, we measured the frequency of apoptotic V␤14 ϩ CD4 T cells in either vacvGimmunized WT or gld mice after RSV challenge. Fig. 9 demonstrates that a greater frequency ( p Ͻ 0.05) of V␤14 ϩ CD4 T cells in the MedLN of gld mice stained positive for activated caspase 3/7 and Annexin V, indicating that a greater proportion of these cells were apoptotic as compared with WT mice at day 5 after RSV challenge (Fig. 9, B-D) . However, there was no significant difference ( p Ͼ 0.05) between the frequency of either caspase 3/7-or Annexin V-positive V␤14 ϩ CD4 T cells in either the lung or the BAL. Taken together these data suggest that secondary effector CD4 T cells lacking functional expression of FasL fail to expand to their full capacity because of an increased rate of apoptosis in the draining lymph nodes.
Discussion
CD4 T cells are critical for mediating the development of RSV vaccine-enhanced disease including pulmonary eosinophilia and systemic disease (as measured by weight loss) (6 -8, 25, 31) . We demonstrate in this study that FasL is required for the development of RSV vaccine-enhanced disease. Both FI-RSV-and vacvG-immunized gld mice exhibit reduced levels of pulmonary eosinophilia as compared with their WT counterparts (Figs. 1 and 3) . Furthermore, vacvG-immunized gld mice have a dramatically decreased number of pulmonary RSV G 183 -specific IFN-␥-and IL-13-producing CD4 T cells as compared with WT mice after RSV challenge (Fig. 3) . Taken together these data suggest that FasL is required for the expansion and/or the survival of RSV-specific secondary effector CD4 T cells that are necessary for the development of RSV vaccine-enhanced disease.
FasL has been demonstrated to play a role in the development of immunopathology and viral clearance after acute RSV infection. The gld mice lose significantly less weight and exhibit a delay in viral clearance after acute infection as compared with WT mice (19) . Interestingly, this response is also accompanied by prolonged production of inflammatory chemokines and IFN-␥, but not TNF-␣. It is currently unclear how these specific inflammatory mediators are elicited in the absence of functional FasL or how these differences play a role in viral clearance and the development of systemic disease. In a CD8 T cell adoptive transfer system, RSV-specific CD8 T cells lacking functional FasL did not differ in their ability to either induce immunopathology or clear virus as compared with WT CD8 T cells, suggesting that CD8 T cell expression of FasL is not required for either CD8 T cell-mediated immunopathology or reduction of viral load (32) . However, our data suggest that FasL expression on CD4 T cells may play a role in the induction of CD4 T cell-mediated immunopathology. The reduced immunopathology, decreased level of pulmonary eosinophilia, and delayed viral clearance exhibited by vacvG-immunized gld mice correlates with the diminished magnitude of the secondary RSV G 183 -specific CD4 T cell response after RSV challenge as compared with WT controls (Fig. 3E) . Interestingly, vacvG-immunized WT and gld mice have similar total numbers of RSV G 183 -specific CD4 T cells at 8 and 21 days after immunization with vacvG (Fig. 5) . These data suggest that the secondary expansion of RSV-specific memory CD4 T cells requires functional FasL. However, it is currently unclear whether or not FasL expression on RSV-specific memory CD4 T cells is required for their full secondary expansion after RSV challenge, or whether or not FasL expression on other cells (i.e., dendritic cells) is required for this full expansion. Legge and Braciale (18) demonstrated that IL-12p40-regulated expression of FasL on lymph node dendritic cells suppressed proliferation of influenza virus-specific CD8 T cells after influenza virus infection. Furthermore, gld mice infected with influenza virus exhibited an enhanced CD8 T cell response as compared with WT control mice (18) . This contrasts with our data demonstrating that the secondary RSV G-specific CD4 T cell response is suppressed in the absence of FasL (Fig. 3) . These results may suggest that FasL expression on lymph node dendritic cells does not directly affect the secondary RSV G-specific response, but rather FasL expression on RSV G-specific CD4 T cells is important for their secondary expansion and survival.
Previous studies have demonstrated that both Fas-mediated caspase cleavage and bidirectional signaling through FasL are required for full proliferative responses of T cells in various systems (16, (33) (34) (35) (36) (37) (38) (39) . In Fig. 9 we examined the frequency of apoptotic V␤14 ϩ CD4 T cells after RSV challenge of vacvG-immunized WT or gld mice. An enhanced frequency of V␤14 ϩ CD4 T cells in the MedLN of gld mice after RSV challenge exhibit activated caspase 3/7 and are AnnexinV-positive as compared with their WT counterparts suggesting that a higher frequency of these cells are apoptotic. Interestingly, there was no difference in the frequency of apoptotic V␤14
ϩ CD4 T cells in either the lungs or the BAL of vacvG-immunized WT or gld mice after RSV challenge (Fig. 9) .
Wissinger et al. (30) demonstrated that memory RSV G 183 -specific CD4 T cells, as identified by their expression of the V␤14 TCR chain, are reactivated in the lung draining lymph nodes and then traffic to the lungs and proliferate after RSV challenge of mice previously immunized with vacvG. These data may indicate that RSV-specific memory CD4 T cells migrate to the draining lymph nodes and subsequently receive survival signals via FasL before their migration to the lung.
Recent work from our laboratory has demonstrated that eosinophils elicited during the development of RSV vaccine-enhanced disease do not contribute to systemic illness (i.e., weight loss or clinical illness) (40) . Our current results further support these findings. The gld mice exhibit reduced CD4 T cell responses that correlate with reduced weight loss and clinical illness scores indicating that the RSV-specific memory CD4 T cell response is an important determinant in mediating systemic disease in this model (Figs. 1 and 3) .
In Fig. 3 we demonstrated that RSV-specific memory CD4 T cells require FasL for full expansion after RSV challenge. Interestingly, the secondary expansion of RSV-specific memory CD8 T cells did not require the expression of functional FasL (Fig. 6 ). This result may be partially explained by differential FasL expression patterns in CD4 and CD8 T cells. Upon primary activation of a CD8 T cell through the TCR, FasL is produced and stored in the secretory lysosome (41) . Upon subsequent contact with an infected host cell, these FasL-containing lysosomes are transported to the cell membrane where FasL is subsequently expressed. In this scenario, FasL would be unavailable for signaling upon initial contact with a Fas-positive Ag-bearing APC, suggesting that CD8 T cells may have evolved other mechanisms to efficiently expand after initial Ag encounter. FasL expression on Th1 CD4 T cell clones is largely on the cell surface after initial Ag activation (41) (42) (43) (44) (45) . Thus when an Ag-specific memory CD4 T cell encounters Ag a second time, FasL is on the cell surface and receptive to a FasL-induced survival signal. However, previous studies have demonstrated a pronounced role for FasL in the primary expansion of CD8 T cells and a minimal role for FasL expression on the primary expansion of CD4 T cells (15) (16) (17) . These studies used either in vitro stimulation of CD8 T cells isolated from either WT or gld mice or adoptive transfer of a large number (over 1 ϫ 10 6 ) of OVA-specific OT-1 TCR transgenic T cells (15, 16) . Our studies examined endogenous RSV-specific CD4 and CD8 T cell populations. It is possible that using a high number of TCR transgenic T cells may accentuate a role for FasL in the primary expansion of CD8 T cells that is not present at an endogenous T cell precursor frequency.
The gld mice used in this study develop a lymphoproliferative disease that results in a large population of CD4 and CD8 double negative T cells expressing B220 (20) . These cells have been demonstrated in vitro to inhibit the proliferation of T cells by inhibiting their ability to respond to IL-2 signals (46) . Although this response may be occurring in vacvG-immunized gld mice, it only affects RSV-specific memory CD4 T cells, as memory RSV-specific CD8 T cell responses are unaltered (Fig. 6) . Furthermore, studies examining the regulatory ability of CD4 and CD8 double negative T cells have noted that their regulatory ability requires direct activation through their TCR (46, 47) . In our experiments, these T cells did not produce IFN-␥ after in vitro stimulation with either G [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] or M2 82-90 peptides (data not shown). These data indicate that it is less likely that these B220 ϩ double negative T cells are inhibiting RSV-specific memory T cell responses.
Memory CD4 T cells cause immunopathology in a number of model systems including experimental autoimmune encephalomyelitis. Similar to our data that FasL is required for the development of CD4 T cell-mediated pathology in RSV vaccine-enhanced disease, the severity of experimental autoimmune encephalomyelitis in gld mice is markedly reduced as compared with WT controls (48) . These data suggest that FasL may be required for full expansion of CD4 T cells that cause immunopathology in other model systems. Therefore, therapeutic blockade of FasL in disease states mediated by memory CD4 T cells may reduce immunopathology and improve clinical outcome.
